Search

Your search keyword '"Biagini, R."' showing total 4 results
Start Over Author "Biagini, R." Region europe
4 results on '"Biagini, R."'

1. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study.

Author

Hompland I, Ferrari S, Bielack S, Palmerini E, Hall KS, Picci P, Hecker-Nolting S, Donati DM, Blattmann C, Bjerkehagen B, Staals E, Kager L, Gambarotti M, Kühne T, Eriksson M, Ferraresi V, Kevric M, Biagini R, Baumhoer D, Brosjø O, Comandone A, Schwarz R, Bertulli R, Kessler T, Hansson L, Apice G, Heydrich BN, Setola E, Flörcken A, Ruggieri P, Krasniqi F, Hofmann-Wackersreuther G, Casali P, Reichardt P, and Smeland S

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms mortality, Bone Neoplasms pathology, Chemotherapy, Adjuvant, Chondrosarcoma mortality, Chondrosarcoma secondary, Disease-Free Survival, Europe, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms therapy, Cell Dedifferentiation, Chondrosarcoma therapy, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy mortality
Abstract

Introduction: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study., Materials and Methods: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models., Results: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42-65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22-25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles., Conclusions: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S.B. has reported grants from Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft and the European Science Foundation and personal fees from Lilly, Bayer, Pfizer, Novartis, Isofol and Clinigen; E.P. has reported advisory roles for Amgen, Daiichi Sankyo, Eli Lilly, EUSA Pharma and Deciphera, received research support from Bristol Myers Squibb, Pfizer and PharmaMar and received travel support from Lilly, PharmaMar and Takeda; L.K. has reported honoraria from Bayer; P.R. has reported advisory roles for Exactech and Stryker; A.F. has reported honoraria from Ipsen Pharma, PharmaMar and Lilly; P.C. has reported honoraria for the speaker, consultancy or advisory role from Bayer, Deciphera, Eisai, Eli Lilly, Nektar Therapeutics and Pfizer and received research funds from Advenchen Laboratories, Amgen Dompé, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc., Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer and PharmaMar; P.R. has reported honoraria from Bayer, Clinigen, BMS, Roche, MSD, Deciphera, Novartis, Pfizer, PharmaMar, Lilly and Amgen; I.H., S.F., K.S.H., P.P., S.H.-N., D.M.D., C.B., B.B., E.St., M.G., T.K., M.E., V.F., M.K., R.B., D.B., O.B., A.C., R.S., R.B., T.K., L.H., G.A., B.-N.H., E.Se., A.F., F.K., G.H.-W. and S.S. have declared no conflicts of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

2. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Author

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, and Blay JY

Subjects
Adult, Aftercare methods, Aftercare standards, Antineoplastic Combined Chemotherapy Protocols standards, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant standards, Digestive System Surgical Procedures methods, Digestive System Surgical Procedures standards, Endosonography, Europe, Gastrointestinal Stromal Tumors diagnosis, Gastrointestinal Stromal Tumors epidemiology, Gastrointestinal Stromal Tumors pathology, Humans, Image-Guided Biopsy methods, Image-Guided Biopsy standards, Incidence, Intestines diagnostic imaging, Intestines pathology, Intestines surgery, Laparoscopy methods, Laparoscopy standards, Margins of Excision, Medical Oncology methods, Neoplasm Staging, Self-Help Groups standards, Societies, Medical standards, Stomach diagnostic imaging, Stomach pathology, Stomach surgery, Tomography, X-Ray Computed, Treatment Outcome, Gastrointestinal Stromal Tumors therapy, Medical Oncology standards, Patient Participation
Published
2018
Full Text
View/download PDF

3. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Author

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, and Blay JY

Subjects
Adult, Aftercare methods, Aftercare standards, Age Factors, Antineoplastic Combined Chemotherapy Protocols standards, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Bone Neoplasms diagnosis, Bone Neoplasms epidemiology, Bone Neoplasms pathology, Bone and Bones diagnostic imaging, Bone and Bones pathology, Bone and Bones surgery, Child, Europe, Humans, Incidence, Long-Term Care methods, Long-Term Care standards, Magnetic Resonance Imaging, Medical Oncology methods, Neoadjuvant Therapy methods, Neoadjuvant Therapy standards, Neoplasm Staging, Orthopedic Procedures methods, Orthopedic Procedures standards, Osteosarcoma diagnosis, Osteosarcoma epidemiology, Osteosarcoma pathology, Positron Emission Tomography Computed Tomography, Radionuclide Imaging, Radiotherapy, Adjuvant methods, Radiotherapy, Adjuvant standards, Self-Help Groups standards, Societies, Medical standards, Survivorship, Treatment Outcome, Bone Neoplasms therapy, Medical Oncology standards, Osteosarcoma therapy, Patient Participation
Published
2018
Full Text
View/download PDF

4. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Author

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, and Blay JY

Subjects
Adult, Aftercare methods, Aftercare standards, Antineoplastic Combined Chemotherapy Protocols standards, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Europe, Humans, Incidence, Lymphatic Metastasis diagnostic imaging, Lymphatic Metastasis pathology, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging standards, Medical Oncology methods, Neoadjuvant Therapy methods, Neoadjuvant Therapy standards, Neoplasm Grading, Neoplasm Staging, Radiotherapy, Adjuvant methods, Radiotherapy, Adjuvant standards, Sarcoma diagnosis, Sarcoma epidemiology, Sarcoma pathology, Self-Help Groups standards, Societies, Medical standards, Surgical Procedures, Operative methods, Surgical Procedures, Operative standards, Tomography, X-Ray Computed methods, Tomography, X-Ray Computed standards, Treatment Outcome, Medical Oncology standards, Patient Participation, Sarcoma therapy
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results